Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

Pharvaris (PHVS) will present clinical and real-world data at the ACAAI Annual Scientific Meeting, scheduled for November 12–16, 2026, in Phoenix, Arizona.

Rhea-AI Summary

Pharvaris (PHVS) will present clinical and real-world data at the ACAAI Annual Scientific Meeting, scheduled for November 12–16, 2026, in Phoenix, Arizona. One abstract was accepted for an oral presentation and five for poster presentations.

The pivotal Phase 3 CHAPTER-3 study of oral deucrictibant extended-release tablets for preventing hereditary angioedema (HAE) attacks will feature in a late-breaking oral presentation by Marc A. Riedl on November 14 at 5:33 p.m. MST. Poster topics include immediate-release deucrictibant for on-demand treatment, HAE economic burden and treatment patterns, final results from the CHAPTER-1 open-label extension, cardiovascular safety, and evaluation of combined immediate-release and extended-release dosing. Posters and slides will be available on the company’s investor website when the respective presentations begin.

Key Figures

Accepted presentations: 1 oral and 5 poster presentations

Accepted presentations

1 oral and 5 poster presentations

ACAAI 2026 Annual Scientific Meeting

Key Terms

hereditary angioedema, c1 inhibitor deficiency, bradykinin b2 receptor antagonists, prophylaxis

4 terms

hereditary angioedema medical

"diseases such as hereditary angioedema (HAE)"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

c1 inhibitor deficiency medical

"acquired angioedema due to C1 inhibitor deficiency"

A deficiency of the C1 inhibitor is a medical condition where a key protein that acts like a brake on parts of the immune and inflammation system is missing or not working, causing sudden, sometimes severe episodes of painless or painful swelling in tissues including the skin, gut and airway. It matters to investors because the condition defines markets for specialized diagnostics, long‑term therapies and emergency treatments; changes in approved treatments, pricing or reimbursement can materially affect companies developing drugs, devices or tests for it.

bradykinin b2 receptor antagonists medical

"oral bradykinin B2 receptor antagonists"

Bradykinin B2 receptor antagonists are drugs that block a specific cell receptor which responds to bradykinin, a natural molecule that causes blood vessels to leak, swell and send pain signals; blocking that receptor can reduce swelling, pain and inflammation. For investors, these drugs matter because successful candidates can address acute or chronic conditions with high unmet need, and their clinical trial results, safety profile and regulatory approvals strongly influence a company’s market value—think of the drug as putting a cap on a leaking pipe to stop costly damage.

prophylaxis medical

"extended-release tablet for the prophylaxis of HAE attacks"

Prophylaxis is a medical prevention strategy — a drug, vaccine, device, or procedure given to stop a disease or condition before it starts. For investors, prophylactic products matter because they can create steady, large markets and reduce long‑term healthcare costs; regulatory approval or broader adoption can change demand forecasts much like a new safety feature that becomes standard across an entire industry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14

ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and five abstracts for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, to be held November 12-16, 2026, in Phoenix, Arizona. Among the accepted presentations, data from the pivotal Phase 3 CHAPTER-3 study of oral deucrictibant extended-release tablet for the prophylaxis of HAE attacks will be featured in a late-breaking oral presentation.

Details of the presentations are as follows:

• Title: Early and Sustained Effects of Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks
  Presenter: John Anderson, M.D.
  Format: Poster Presentation
  Date, time: Friday, November 13, 2026, 5:05 p.m. MST (7:05 p.m. EST)

• Title: Economic Burden and Treatment Patterns Among Individuals With Hereditary Angioedema: a U.S. Closed Claims Analysis
  Presenter: Raffi Tachdjian, M.D., MPH
  Format: Poster Presentation
  Date, time: Saturday, November 14, 2026, 12:45 p.m. MST (2:45 p.m. EST)

• Title: Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks: The Phase 3 CHAPTER-3 Trial
  Presenter: Marc A. Riedl, M.D., M.S.
  Format: Oral Presentation
  Date, time: Saturday, November 14, 2026, 5:33 p.m. MST (7:33 p.m. EST)

• Title: Oral Deucrictibant for Prophylaxis of Hereditary Angioedema Attacks: Final Results From the CHAPTER-1 Open-Label Extension
  Presenter: Michael E. Manning, M.D.
  Format: Poster Presentation
  Date, time: Sunday, November 15, 2026, 11:45 a.m. MST (1:45 p.m. EST)

• Title: Clinical Cardiovascular Safety Evaluation of Oral Deucrictibant
  Presenter: Anne Lesage, Ph.D.
  Format: Poster Presentation
  Date, time: Sunday, November 15, 2026, 12:15 p.m. MST (2:15 p.m. EST)

• Title: Evaluation of Safety Margins and Response to Deucrictibant Immediate-Release Capsule Combined With Deucrictibant Extended-Release Tablet
  Presenter: Anne Lesage, Ph.D.
  Format: Poster Presentation
  Date, time: Sunday, November 15, 2026, 12:30 p.m. MST (2:30 p.m. EST)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Vice President, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com